Targeting the Undruggable
SyntheX uses the power of genetics and synthetic biology to build the next generation of drug discovery engines.
We discover and develop therapeutics for conventionally undruggable targets using functional selection to target currently inaccessible mechanisms of action.
OUR TECHNOLOGY
We have developed ToRPPIDO to discover disruptors of protein-protein interactions, and ToRNeDO to discover molecular glue-based functional protein degraders using a pre-specified E3 ligase and a neosubstrate of interest.
Our platforms can use canonical small molecule HTS approaches or select from our proprietary genetically encoded peptide and rigidified scaffold libraries of billions of compounds.
OUR PIPELINE
Our internal programs are focused on oncology. We select genetically validated targets based on the concepts of oncogene addiction and synthetic lethality.
The goal of our approach is to minimize clinical resistance pathways by modulating established targets in orthogonal ways.
THE LEADERSHIP TEAM
Co-Founder & CEO
Co-Founder & CSO
Head of Finance & Operations
VP of Drug Discovery
SCIENTIFIC ADVISORY BOARD
Andrew Perlman, MD, PhD
OUR INVESTORS
INCUBATOR & ACCELERATOR SUPPORT
OPEN POSITIONS
Imagine. Design. Build. Create.
Are you an enthusiastic scientist who's excited about using synthetic biology to advance drug discovery?
We are always keeping an eye out for talented members to join our growing team.
RESEARCH ASSISTANTS (BS or MS):
-
Molecular Biology
-
Biochemistry
-
Cell Biology
-
Peptide Chemistry
RESEARCH SCIENTISTS (PhD+):
-
Proteomics
-
Enzyme Engineering
-
Microbial Genetics
-
Biochemistry
-
Cancer Cell Biology
GET IN TOUCH
